

SUPPORT FOR THE AMENDMENTS

Applicants have amended Claim 1 to read upon the election of A being -S- and V-W being C=C. Accordingly, support for amended Claim 1 can be found in the same claim, as originally filed. Claims 2-6, 8, 12, and 19 have been amended to properly depend from amended Claim 1. Support for amended Claims 2-6, 8, 12, and 19 can be found in the same claims, as originally filed. Claims 13-18 have been amended to depend from Claims 2-6 and 8, respectively. Claims 22-26 have been amended to depend from Claims 3-6 and 8, respectively. Support for amended Claims 13-18 and 22-26 can be found in the same claims, as originally filed.

Applicants have also added new Claims 27-38. Support for new Claims 27, 31, and 35 can be found in Claims 10, 18 and 26, as originally filed. Support for new Claim 28-30, 32-34, and 36-38 can be found in Examples 76, 77, and 81 and Claims 11 and 20, as originally filed.

No new matter has been added. Claims 1-6, 8, and 12-38 are pending in this application.

REMARKS/ARGUMENTS

At the outset, Applicants wish to thank Examiner Chang for indicating that the claims are free of the prior art. Applicants respectfully submit that, in view of the present amendments and remarks, the present claims are fully patentable.

The provisional rejection of Claims 20-22, 24, and 26 under the judicially-created doctrine of obviousness-type double patenting in view of Claims 1-12 of co-pending U.S. Patent Application Serial No. 10/911,633 in view of WO 99/37296 supplemented with Vega-Hernandez et al. and Sutton et al. is respectfully traversed. Quite simply, as explained in detail below, all of the pending claims are now otherwise allowable. Accordingly, the only

rejection remaining in this application is the provisional obviousness-type double patenting rejection. Thus, this rejection should be withdrawn under MPEP § 804, subsection I.B.

The rejection of Claims 1-3, 5, 8, and 10 as containing non-elected compounds has been obviated by appropriate amendment. As the Examiner will note, Applicants have amended Claim 1 to define A as -S- and V-W as -C=C-. Moreover, all of Claims 2-6, 8, and 12-26 have been amended to properly depend, either directly or indirectly, from amended Claim 1. Accordingly, Claims 4 and 6 should be rejoined as they are now directed to the elected compounds, and all of Claims 1-6 and 8 should be allowed. Similarly, Claim 10 has been replaced with Claim 27 which is now limited to the elected compounds. Accordingly, Claim 27 should also now be allowed.

Further all of the pharmaceutical composition claims, Claims 20-26 now properly depend, either directly or indirectly, from amended Claim 1. Accordingly, any withdrawn pharmaceutical composition claims should be rejoined, and all of Claims 20-26 and 35-38 should be allowed.

Lastly, all of the method claims, Claims 12-19 and 31-34 now properly depend, either directly or indirectly, from amended Claim 1. Moreover, Claim 1 is now clearly allowable. Accordingly, any withdrawn pharmaceutical composition claims should be rejoined under MPEP § 821.04, and all of Claims 12-19 and 31-34 should be allowed.


Application No. 10/787,175

Reply to Office Action dated December 22, 2006

Applicants submit that the present application is now in condition for allowance, and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter
Attorney of Record
Registration No. 32,884

Customer Number

22850

Tel: (703) 413-3000

Fax: (703) 413 -2220